Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
1.
Br J Anaesth ; 115(3): 457-62, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26205902

RESUMO

BACKGROUND: Peripheral nerve catheters (PNCs) are used with increasing frequency in children. Although adult studies have demonstrated safety with this technique, there have been few safety studies in children. The main objective of the current investigation was to examine the incidence of PNC complications in children undergoing surgery. METHODS: This is an observational, multi-institutional study using the Pediatric Regional Anesthesia Network (PRAN) database. Data pertaining to PNCs were entered prospectively into a secure, online database by each participating centre. Patient characteristics, anatomic location, localization techniques, medications used, and complications were recorded for each catheter. All complications and any sequelae were followed until resolution. RESULTS: There were 2074 PNCs included in the study. 251 adverse events and complications were recorded, resulting in an overall incidence (95% CI) of complications of 12.1% (10.7-13.5%). The most common complications were catheter malfunction, block failure, infection, and vascular puncture. There were no reports of persistent neurologic problems, serious infection, or local anaesthetic systemic toxicity, resulting in an estimated incidence (95% CI) of 0.04% (0.001-0.2%). Patients who developed an infection had used the catheters for a greater number of days, median (IQR) of 4.5 (3-7) days compared with 3 (1-3) days in the patients who did not develop an infection, P<0.0001. CONCLUSIONS: Our data support the safety of placing PNCs in children, with adverse event rates similar to adult studies. Catheter problems are common, yet minor, in severity.


Assuntos
Anestesia por Condução/efeitos adversos , Anestesia por Condução/estatística & dados numéricos , Bloqueio Nervoso/efeitos adversos , Bloqueio Nervoso/estatística & dados numéricos , Nervos Periféricos , Padrões de Prática Médica/estatística & dados numéricos , Adolescente , Infecções Bacterianas/epidemiologia , Catéteres/efeitos adversos , Criança , Bases de Dados Factuais , Falha de Equipamento , Feminino , Humanos , Masculino , Estudos Prospectivos , Fatores de Tempo
2.
Intern Med J ; 37(5): 303-7, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17504277

RESUMO

BACKGROUND: Thyrotoxic, hypokalaemic periodic paralysis (TPP) is a reversible cause of severe muscle weakness that occurs in a small minority of thyrotoxic patients. Most cases to date have been reported in Asian men. AIMS: To evaluate the ethnic distribution of patients with TPP. METHODS: Retrospective analysis of all patients presenting with thyrotoxicosis and hypokalaemia with paralysis to two New Zealand hospitals. RESULTS: Seventy-one per cent of the 21 patients with TPP were of Polynesian ethnicity (Maori and Pacific Islander), 24% Asian and 5% European. Based on population demographics, these figures suggest a 37-fold overrepresentation for Polynesians and 159-fold for Asians compared with New Zealand Europeans. CONCLUSION: Polynesian, in addition to Asian people, are two ethnic groups at particular risk of TPP, and this condition must be considered in the differential diagnosis for patients presenting to the emergency department with severe hypokalaemia and weakness.


Assuntos
Paralisia Periódica Hipopotassêmica/etnologia , Tireotoxicose/etnologia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nova Zelândia , Polinésia , Estudos Retrospectivos
3.
Osteoporos Int ; 18(4): 479-86, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17120180

RESUMO

SUMMARY: We performed a 2-year extension of our previous 2-year randomized controlled trial of the effects of hydrochlorothiazide on bone mineral density. The improvements in bone density seen in the first 2 years were sustained throughout the extension study. Thiazides provide a further option in the prevention of postmenopausal bone loss. INTRODUCTION: Thiazide diuretics reduce urinary calcium excretion and therefore might prevent osteoporosis. Previously we reported a 2-year randomized controlled trial of hydrochlorothiazide treatment in 185 postmenopausal women that showed positive benefits of hydrochlorothiazide on bone density. Here, we report the results of a 2-year extension to that study. METHODS: Of 185 healthy postmenopausal women, 122 agreed to continue in a double-blinded 2-year extension taking 50 mg hydrochlorothiazide or placebo daily. Measurements of bone density occurred every 6 months and of calcium metabolism at 2 and 4 years. RESULTS: The improvements in bone density seen in the first 2 years of the trial were sustained throughout the extension. There were significant between-groups differences in the change in bone density over 4 years at the total body (0.9%, P<0.001), legs (1.0%, P=0.002), mid-forearm (1.1%, P=0.03), and ultradistal forearm (1.4%, P=0.04). At the lumbar spine (0.9%, P=0.76) and femoral neck (0.4%, P=0.53) the between-groups differences did not reach statistical significance. CONCLUSIONS: Hydrochlorothiazide produces small positive benefits on cortical bone density that are sustained for at least the first 4 years of treatment. They provide a further option in the prevention of postmenopausal bone loss, especially for women with hypertension or a history of kidney stones.


Assuntos
Densidade Óssea/efeitos dos fármacos , Hidroclorotiazida/uso terapêutico , Pós-Menopausa/fisiologia , Inibidores de Simportadores de Cloreto de Sódio/uso terapêutico , Análise Química do Sangue/métodos , Reabsorção Óssea/fisiopatologia , Reabsorção Óssea/prevenção & controle , Cálcio/metabolismo , Método Duplo-Cego , Feminino , Fraturas Ósseas/prevenção & controle , Humanos , Hidroclorotiazida/efeitos adversos , Ossos da Perna/fisiologia , Assistência de Longa Duração/métodos , Pessoa de Meia-Idade , Osteoporose Pós-Menopausa/prevenção & controle , Inibidores de Simportadores de Cloreto de Sódio/efeitos adversos , Coluna Vertebral/fisiologia , Resultado do Tratamento
4.
Am J Med ; 109(5): 362-70, 2000 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-11020392

RESUMO

PURPOSE: Thiazide diuretics reduce urine calcium excretion and might therefore reduce postmenopausal bone loss. In some, but not all, case-control studies, their use has been associated with a reduced incidence of hip fractures. We studied the effects of hydrochlorothiazide on bone loss in normal postmenopausal women. SUBJECTS AND METHODS: We performed a randomized, double-blind, 2-year trial of the effects of hydrochlorothiazide (50 mg per day) and placebo on bone mineral density in normal postmenopausal women. Participants were not required to have either low bone mineral density or hypertension. Bone mineral density was measured using dual-energy x-ray absorptiometry. RESULTS: One hundred eighty-five women entered the study, of whom 138 completed 2 years of follow-up. In an intention-to-treat analysis, hydrochlorothiazide produced significant benefits on bone mineral density of the total body (between-group difference at 2 years of 0.8%, 95% confidence interval [CI]: 0.3% to 1.3%, P <0.0001), legs (0.9%, 95% CI: 0.2% to 1.7%, P <0.0001), mid-forearm (1.2%, 95% CI: 0.2% to 2.2%, P = 0.02), and ultradistal forearm (1.7%, 95% CI: 0.1% to 3.2%, P = 0.04). There was no effect in the lumbar spine (0.5%, 95% CI: -0.5% to 1.6%) or femoral neck (0.2%, 95% CI: 1.3% to 1.7%). The between-group changes tended to be greatest during the first 6 months, except in the mid-forearm where there appeared to be a progressive divergence. An as-treated analysis produced similar results. Urine calcium excretion and indices of bone turnover decreased in the thiazide group, but parathyroid hormone concentrations did not differ between the groups. Treatment was tolerated well. CONCLUSIONS: Hydrochlorothiazide (50 mg per day) slows cortical bone loss in normal postmenopausal women. It may act directly on bone as well as on the renal tubule. The small size of the effect suggests that thiazides may have a role in the prevention of postmenopausal bone loss, but that they are not an appropriate monotherapy for treating osteoporosis.


Assuntos
Densidade Óssea/efeitos dos fármacos , Cálcio/metabolismo , Hidroclorotiazida/farmacologia , Menopausa/metabolismo , Osteoporose Pós-Menopausa/prevenção & controle , Inibidores de Simportadores de Cloreto de Sódio/farmacologia , Absorciometria de Fóton , Idoso , Diuréticos , Método Duplo-Cego , Esquema de Medicação , Feminino , Colo do Fêmur/metabolismo , Humanos , Hidroclorotiazida/administração & dosagem , Vértebras Lombares/metabolismo , Pessoa de Meia-Idade , Osteoporose Pós-Menopausa/metabolismo , Valores de Referência , Inibidores de Simportadores de Cloreto de Sódio/administração & dosagem , Fatores de Tempo , Resultado do Tratamento
5.
Biochem Biophys Res Commun ; 276(3): 1235-9, 2000 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-11027616

RESUMO

We have previously reported the asymmetric synthesis of (alpha-aminoalkyl) diphenylphosphonate and phosphinate derivatives designed as inhibitors of chymotrypsin- and elastase-like proteases. This paper reports the first kinetic evaluation of individual epimers of the (alpha-aminoalkyl) diphenylphosphonates as inactivators of chymotrypsin, cathepsin G and neutrophil elastase (HNE). Results show that the (R)-epimers consistently function as more potent irreversible inactivators of their respective target proteases than the corresponding (S)-epimers. Additionally, phosphinate analogues were found to be consistently superior to their diphenylphosphonate counterparts. For example, Cbz. Phe(P)(OPh)-(CH(2))(2)-CO(2)Et inactivates cathepsin G approximately 45-fold more rapidly (k(i)/K(i) = 1.2 x 10(5) M(-1). min(-1)) than the analogous Cbz.Phe(P)(OPh)(2) (2.6 x 10(3) M(-1). min(-1)). Similarly, Cbz.Val(P)(OPh)-(CH(2))(2)-CO(2)Et was found to inactivate HNE some 3-fold more efficiently than Cbz.Val(P)(OPh)(2) (6.5 x 10(3) and 2.0 x 10(3) M(-1). min(-1), respectively).


Assuntos
Organofosfonatos/química , Organofosfonatos/metabolismo , Ácidos Fosfínicos/química , Ácidos Fosfínicos/metabolismo , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/farmacologia , Catepsina G , Catepsinas/antagonistas & inibidores , Catepsinas/metabolismo , Criança , Quimotripsina/antagonistas & inibidores , Quimotripsina/metabolismo , Fibrose Cística/enzimologia , Humanos , Hidrólise/efeitos dos fármacos , Isomerismo , Cinética , Elastase de Leucócito/antagonistas & inibidores , Elastase de Leucócito/metabolismo , Organofosfonatos/farmacologia , Ácidos Fosfínicos/farmacologia , Inibidores de Serina Proteinase/metabolismo , Especificidade por Substrato
6.
Arch Intern Med ; 160(14): 2161-6, 2000 Jul 24.
Artigo em Inglês | MEDLINE | ID: mdl-10904459

RESUMO

BACKGROUND: Long-term treatment of patients with asymptomatic primary hyperparathyroidism remains controversial, but the presence of osteoporosis is regarded as an indication for parathyroidectomy. Hormone replacement therapy (HRT) is a possible alternative therapy in osteopenic postmenopausal women with the disorder, and results of short-term studies suggest a beneficial effect on bone mass comparable to that achieved by parathyroidectomy. Longer-term data are required to further assess the efficacy of this treatment in chronic stable primary hyperparathyroidism. METHODS: We report the results of the extension from 2 to 4 years of a randomized, placebo-controlled trial of HRT in postmenopausal women with primary hyperparathyroidism. Of 23 postmenopausal women with primary hyperparathyroidism, 11 received active HRT with conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 5 mg/d, and 12 received placebo. Bone mineral density was measured throughout the skeleton at 6-month intervals using dual-energy x-ray absorptiometry in these women and in 50 normocalcemic age-matched control subjects. None of the 23 patients withdrew during the extension period. RESULTS: Changes in bone mineral density were more positive in those taking HRT than placebo, with the between-group differences at 4 years being 4.6% in the total body, 7.5% in the lumbar spine, 7.4% in the femoral neck, 8.2% in the femoral trochanter, 6.8% in the legs, and 7.0% in the forearm (P<.01). At skeletal sites composed predominantly of cortical bone, there was a progressive divergence of the 2 groups. Biochemical markers of bone turnover remained lower throughout the study in women taking HRT. When rates of bone loss were compared between the placebo group and healthy women of comparable age, bone loss tended to be more marked throughout the skeleton in women with hyperparathyroidism, but only in the total body and its legs subregion was this difference significant. CONCLUSIONS: Hormone replacement therapy is efficacious in the long-term management of osteopenia in postmenopausal women with primary hyperparathyroidism and thus represents an important new therapeutic option for asymptomatic patients who do not have other indications for surgery. Bone loss seems to be accelerated in untreated primary hyperparathyroidism.


Assuntos
Densidade Óssea/efeitos dos fármacos , Estrogênios Conjugados (USP)/uso terapêutico , Terapia de Reposição Hormonal , Hiperparatireoidismo/metabolismo , Acetato de Medroxiprogesterona/uso terapêutico , Osteoporose Pós-Menopausa/prevenção & controle , Pós-Menopausa , Absorciometria de Fóton , Idoso , Índice de Massa Corporal , Quimioterapia Combinada , Feminino , Seguimentos , Humanos , Hiperparatireoidismo/complicações , Osteoporose Pós-Menopausa/etiologia , Osteoporose Pós-Menopausa/metabolismo , Pós-Menopausa/efeitos dos fármacos , Pós-Menopausa/metabolismo , Congêneres da Progesterona/uso terapêutico , Resultado do Tratamento
7.
J Clin Endocrinol Metab ; 84(6): 1997-2001, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10372700

RESUMO

Menopause is associated with an increase in venous bicarbonate concentrations that is reversible with hormone replacement therapy (HRT). However, the mechanism underlying this effect is not known. To address this question, we studied the changes in acid-base indexes in the arterialized venous blood of normal postmenopausal women commencing conjugated equine estrogen (0.625 mg/day), medroxyprogesterone acetate (MPA; 5 mg/day), their combination, or placebo, in a double blind randomized controlled study over 3 months. Serum bicarbonate concentrations decreased significantly in the groups receiving either MPA or estrogen plus MPA (P = 0.008). This trend was apparent as early as 2 days and reached 2.7 and 2.3 mmol/L in the respective groups by 3 months. Similar changes were seen with partial pressure of carbon dioxide (P = 0.04); a change of -0.7 kPa occurred in the estrogen plus MPA group at 3 months. There were no changes in bicarbonate concentrations or partial pressure of carbon dioxide in those receiving estrogen alone or placebo. Accompanying changes in blood pH were apparent in the estrogen plus MPA group, where there was an upward trend at 1 week (P = 0.056) and a significant change from baseline (+0.013) at 3 months (P = 0.03). In the whole group, the changes in pH were inversely correlated with those in urinary excretion of hydroxyproline (r = -0.44; P = 0.01). We conclude that HRT using conjugated estrogens and MPA produces small, but sustained, changes in acid-base status. These may contribute to the effects of HRT and menopause on many tissues and disease processes, including the development of osteoporosis.


Assuntos
Alcalose Respiratória/induzido quimicamente , Terapia de Reposição de Estrogênios/efeitos adversos , Pós-Menopausa/metabolismo , Equilíbrio Ácido-Base/efeitos dos fármacos , Cálcio/metabolismo , Cálcio/urina , Método Duplo-Cego , Quimioterapia Combinada , Estrogênios/efeitos adversos , Estrogênios/uso terapêutico , Feminino , Humanos , Acetato de Medroxiprogesterona/efeitos adversos , Acetato de Medroxiprogesterona/uso terapêutico , Pessoa de Meia-Idade , Congêneres da Progesterona/efeitos adversos , Congêneres da Progesterona/uso terapêutico
8.
Clin Endocrinol (Oxf) ; 49(5): 615-8, 1998 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10197077

RESUMO

OBJECTIVE: Depot medroxyprogesterone acetate (DMPA), an injectable progestogen, is a widely used contraceptive acting primarily by inhibiting secretion of pituitary gonadotrophins, thus producing oestrogen deficiency. Cross-sectional and prospective studies in pre-menopausal women have shown DMPA use to be associated with reduced bone density, but bone density increases following discontinuation of the drug. Because fracture rates are low in pre-menopausal women, the principal concern arising from the effects of DMPA on bone is that there may be residual osteopenia in former users such that their post-menopausal fracture risk is increased. The present study addresses this question. DESIGN: Cross-sectional study of bone density in post-menopausal former users of DPMA and controls. SUBJECTS: Three hundred and forty-six normal post-menopausal women, of whom 34 had previously used DMPA. The median age at which DMPA use began was 41 years and the median duration of use was 3.0 years. MEASUREMENTS: Bone density was measured in the spine, proximal femur and total body by dual-energy, X-ray absorptiometry. RESULTS: There were no significant differences in bone density at any site between the women who had previously used DMPA and the others in the cohort. However, in those who had used DMPA for > 2 years there was a trend towards bone densities being lower in the former users, the differences from non-users being 1.6% in the lumbar spine (P = 0.6), 3.1% in the femoral neck (P = 0.4) and 0.5% in the total body (P = 0.8). There was no correlation between bone densities and the duration of DMPA use, the age at discontinuation of DMPA, or the time between DMPA discontinuation and the menopause. CONCLUSIONS: Any residual effects of depot medroxyprogesterone acetate use on post-menopausal bone density are small and therefore unlikely to have a substantial impact on fracture risk in the post-menopausal years.


PIP: The possibility that use of depot medroxyprogesterone acetate (DMPA) has residual effects on postmenopausal bone mineral density was assessed in a cross-sectional study of 346 postmenopausal former users of DMPA and controls from Auckland, New Zealand. 34 women (10%) reported past use of DMPA, for a median duration of 3 years, starting at a median age of 41 years. Dual-energy, x-ray absorptiometry failed to reveal significant differences between past users of DMPA and never-users in bone density in the spine, proximal femur, or total body. However, in women who had used DMPA for more than 2 years, there was a nonsignificant trend toward lower bone densities in former users compared with never-users. The difference between mean measurements was 1.6% in the lumbar spine (p = 0.6), 3.1% in the femoral neck (p = 0.4), and 0.5% in the total body (p = 0.8). There was no correlation between bone densities and the duration of DMPA use, age at discontinuation of DMPA use, or the time between DMPA discontinuation and menopause. These findings suggest that any residual effects of DMPA use on postmenopausal bone density are likely to be small and without a substantial impact on fracture risk.


Assuntos
Densidade Óssea/efeitos dos fármacos , Anticoncepcionais Femininos/farmacologia , Acetato de Medroxiprogesterona/farmacologia , Pós-Menopausa , Anticoncepcionais Femininos/efeitos adversos , Estudos Transversais , Feminino , Humanos , Acetato de Medroxiprogesterona/efeitos adversos , Pessoa de Meia-Idade , Fatores de Tempo
9.
Bioorg Med Chem Lett ; 8(13): 1655-60, 1998 Jul 07.
Artigo em Inglês | MEDLINE | ID: mdl-9873408

RESUMO

The synthesis of diphenyl phosphonate analogues of aspartic and glutamic acid, and their inhibitory activity against S. aureus V8 protease and granzyme B, is described. The study has revealed difficulties with protecting group compatibility in the synthesis of these analogues. Two analogues, Acetyl. AspP (OPh)2 and Acetyl.GluP (OPh)2 were found to function as irreversible inactivators of V8 proteinase, yet exhibit no activity against granzyme B.


Assuntos
Ácido Aspártico/análogos & derivados , Ácido Glutâmico/análogos & derivados , Organofosfonatos/síntese química , Organofosfonatos/farmacologia , Inibidores de Proteases/síntese química , Inibidores de Proteases/farmacologia , Catálise , Hidrólise , Cinética , Serina Endopeptidases/efeitos dos fármacos , Serina Endopeptidases/metabolismo
10.
J Clin Endocrinol Metab ; 82(11): 3580-3, 1997 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-9360510

RESUMO

In a recent case-control study, premature hair graying was found to be associated with osteopenia, suggesting that this might be a clinically useful risk factor for osteoporosis. We report a reexamination of this possibility in 293 healthy postmenopausal women. Subjects experiencing onset of hair graying in their 20s tended to have lower bone mineral density throughout the skeleton (adjusted for age and weight) than those with onset of graying later in life. The same was true for those in whom the majority of their hair was gray by the age of 40 yr (n = 16), in whom bone density was reduced by 7% in the femoral neck, 8% in the femoral trochanter, and 4% in the total body (P < 0.05) when compared with those not prematurely gray. Bone density at the lumbar spine and Ward's triangle showed similar trends that were not significant. However, premature hair graying explained only 0.6-1.3% of the variance in bone mineral density within the population. We conclude that premature hair graying is associated with low bone density, but that its infrequency in the normal postmenopausal population leads to its accounting for only a tiny fraction of the variance of bone density.


Assuntos
Densidade Óssea , Cor de Cabelo , Osteoporose Pós-Menopausa/etiologia , Idoso , Idoso de 80 Anos ou mais , Envelhecimento , Feminino , Humanos , Pessoa de Meia-Idade , Pós-Menopausa , Fatores de Risco , Inquéritos e Questionários
11.
Biopharm Drug Dispos ; 13(3): 171-7, 1992 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-1576325

RESUMO

Administration of terfenadine (Seldane) immediately after a high fat breakfast slightly affects the rate but not the extent of absorption relative to fasting administration. Mean peak levels of the active metabolite were increased by 13 per cent but delayed by 0.9 h while AUC was virtually the same as when terfenadine was administered while fasting. Changes in rate of absorption may be due to delayed gastric emptying and more rapid terfenadine solubilization. In any case, these rate differences are unlikely to be clinically important in the absence of differences in extent of absorption.


Assuntos
Gorduras na Dieta/administração & dosagem , Jejum/metabolismo , Terfenadina/farmacocinética , Adulto , Disponibilidade Biológica , Humanos , Absorção Intestinal/efeitos dos fármacos , Masculino , Terfenadina/sangue , Terfenadina/metabolismo
12.
J Clin Pharmacol ; 32(3): 267-71, 1992 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-1564131

RESUMO

The pharmacokinetics of the terfenadine active metabolite, metabolite I, was examined in ten healthy elderly adults and ten younger adults after single-dose oral administration of 120-mg terfenadine. All subjects successfully completed the study without reporting sedation or other adverse events. Absorption was rapid in both the young and elderly. The mean Cmax was the same for both groups, 501 ng/mL, and occurred at 2.3 hours in the young subjects and 2.5 hours in elderly subjects. However, the apparent clearance was reduced by about 25% in the elderly. After correcting clearance for bodyweight, this difference was not statistically significant.


Assuntos
Terfenadina/farmacocinética , Administração Oral , Adulto , Idoso , Peso Corporal , Humanos , Absorção Intestinal , Masculino , Taxa de Depuração Metabólica , Terfenadina/administração & dosagem , Terfenadina/efeitos adversos , Terfenadina/metabolismo , Fatores de Tempo
14.
Genetics ; 128(3): 571-82, 1991 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-1908397

RESUMO

A mutational analysis has been performed to explore the function of the Drosophila melanogaster miniature-dusky (m-dy) locus. Mutations at this locus affect wing development, fertility and behavior. The genetic characterization of 13 different mutations suggests that m and dy variants are alleles of a single complex gene. All of these mutations alter wing size, apparently by reducing the volume of individual epidermal cells of the developing wing. In m mutants, epidermal cell boundaries persist in the mature wing, whereas they normally degenerate 1-2 hr after eclosion in wild-type or dy flies. This has permitted the direct visualization of cell size differences among several m mutants. Mutations at the m-dy locus also affect behavioral processes. Three out of nine dy alleles (dyn1, dyn3 and dyn4) lengthen the circadian period of the activity and eclosion rhythms by approximately 1.5 hr. In contrast, m mutants have normal circadian periods, but an abnormally large percentage of individuals express aperiodic bouts of activity. These behavior genetic studies also indicate that an existing "rhythm" mutation known as Andante is an allele of the m-dy locus. The differential effects of certain m-dy mutations on wing and behavioral phenotypes suggest that separable domains of function exist within this locus.


Assuntos
Ritmo Circadiano/genética , Drosophila melanogaster/genética , Asas de Animais/crescimento & desenvolvimento , Alelos , Animais , Análise Mutacional de DNA , Drosophila melanogaster/crescimento & desenvolvimento , Células Epidérmicas , Feminino , Fertilidade/genética , Teste de Complementação Genética , Masculino , Microscopia Eletrônica de Varredura , Atividade Motora , Fenótipo
16.
Clin Endocrinol (Oxf) ; 23(2): 169-74, 1985 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-2865021

RESUMO

Intravenous infusion of somatostatin in six water loaded normal human subjects produced a prompt reduction in urine flow accompanied by a rise in urine osmolality and a decrease in free water clearance. Plasma AVP levels did not change. Somatostatin would seem to exert an antidiuretic effect directly on the kidney.


Assuntos
Rim/efeitos dos fármacos , Somatostatina/farmacologia , Água/metabolismo , Adulto , Arginina Vasopressina/sangue , Feminino , Humanos , Masculino , Concentração Osmolar , Micção/efeitos dos fármacos
17.
Diabet Med ; 1(4): 298-300, 1984 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-6242821

RESUMO

The possibility of using electroimmunoassay as a technique for assessing microalbuminuria in the diabetic population has been studied. The method was found to be precise (given inter-batch coefficients of variation of 5.7% and 5.8% at levels of 16 mg/l and 23 mg/l respectively), showed adequate sensitivity, and produced results which correlated well (r = 0.971) with these obtained from a routine radioimmunoassay procedure. It is concluded that electroimmunoassay provides a reliable alternative to more sophisticated techniques in the non-specialized laboratory dealing with only moderate numbers of specimens.


Assuntos
Albuminúria/urina , Diabetes Mellitus/urina , Eletroforese , Imunoensaio , Nefropatias Diabéticas/urina , Humanos , Controle de Qualidade , Radioimunoensaio
19.
Arzneimittelforschung ; 32(9a): 1185-90, 1982.
Artigo em Inglês | MEDLINE | ID: mdl-6817765

RESUMO

Comparison of plasma level data obtained from a dose-response study to that of a 14C material balance study indicates that 99.48% of the alpha-[4-(1,1-dimethylethyl)phenyl] 4-(hydroxydiphenylmethyl)-1-piperidinebutanol (terfenadine, RMI 9918, Triludan, Teldane, resp.) related material absorbed undergoes biotransformation. From the balance study it has been determined that fecal excretion accounts for ca. 60% of the dose administered. Thin-layer chromatographic analysis of urine and feces revealed the presence of two major metabolic products. These compounds have been isolated and their structures determined by GC-MS. One of the metabolic products, a carboxylic acid analog of terfenadine has been shown to have antihistaminic activity and may play a role in the activity of the parent drug in vivo.


Assuntos
Compostos Benzidrílicos/metabolismo , Disponibilidade Biológica , Biotransformação , Relação Dose-Resposta a Droga , Fezes/análise , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Cinética , Masculino , Radioimunoensaio , Terfenadina
20.
Biopharm Drug Dispos ; 2(2): 185-90, 1981.
Artigo em Inglês | MEDLINE | ID: mdl-6113858

RESUMO

Fourteen normal male subjects were given either 60mg or 180mg of terfenadine suspension in a randomized two-way crossover study. Peak plasma concentrations of 1.544 +/- 0.726 (mean +/- S.D.) ng ml-1 were obtained in 0.786 h following the 60 mg dose and displayed an AUC or 11.864 +/- 3.369 ng h ml-1. Whereas peak plasma concentrations of 4.519 +/- 2.002 ng ml-1 in 1.071 +/- 0.514 h were obtained following the 180 mg dose. The AUC following the 180 mg dose was 44.341 +/- 22.041 ng h ml-1. When 60 mg of 14C terfenadine was given to six additional subjects, the peak plasma concentrations of 351 +/- 43 ng equivalents per ml were obtained in 1.67 +/- 0.41 h and the AUC was 2297.71 +/- 310.85 ng-equivalents h ml-1. This indicates that approximately 99.5 per cent of the terfenadine related material that is absorbed undergoes biotransformation. Urinary excretion of 14C accounted for 39.89 +/- 5.29 per cent of the dose while 60.58 +/- 2.44 per cent of the dose was recovered in the feces in twelve days. Thin-layer chromatographic (TLC) examination of fecal extracts showed only a trace of material chromatographing with terfenadine. This may indicate that the 14C present in the feces is not due to lack of absorption.


Assuntos
Compostos Benzidrílicos/metabolismo , Antagonistas dos Receptores Histamínicos H1/metabolismo , Piperidinas/metabolismo , Disponibilidade Biológica , Humanos , Cinética , Masculino , Terfenadina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA